MIT

Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner

Retrieved on: 
Tuesday, July 11, 2023

NEW YORK and SOUTH SAN FRANCISCO, Calif., July 11, 2023 /PRNewswire/ -- Apple Tree Partners (ATP), a leader in life sciences venture capital, announced today that Matthew P. Jacobson, Ph.D., serial biotech entrepreneur and Professor Emeritus in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF), has joined ATP as a venture partner. In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies. He will be based in ATP's South San Francisco office.

Key Points: 
  • In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies.
  • Dr. Jacobson's research interests are in the areas of computational biophysics and computer-aided drug design; he is the author of more than 200 publications and several patents.
  • He presently devotes most of his time to biotech entrepreneurship and has co-founded six successful biotech companies in the past dozen years.
  • "We have enjoyed a productive working relationship with Matt for several years, and we are delighted to formally welcome him to ATP as a venture partner and scientific advisor," said Seth Harrison, M.D., Apple Tree Partners' founder and Managing Partner.

Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner

Retrieved on: 
Tuesday, July 11, 2023

NEW YORK and SOUTH SAN FRANCISCO, Calif., July 11, 2023 /PRNewswire/ -- Apple Tree Partners (ATP), a leader in life sciences venture capital, announced today that Matthew P. Jacobson, Ph.D., serial biotech entrepreneur and Professor Emeritus in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF), has joined ATP as a venture partner. In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies. He will be based in ATP's South San Francisco office.

Key Points: 
  • In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies.
  • Dr. Jacobson's research interests are in the areas of computational biophysics and computer-aided drug design; he is the author of more than 200 publications and several patents.
  • He presently devotes most of his time to biotech entrepreneurship and has co-founded six successful biotech companies in the past dozen years.
  • "We have enjoyed a productive working relationship with Matt for several years, and we are delighted to formally welcome him to ATP as a venture partner and scientific advisor," said Seth Harrison, M.D., Apple Tree Partners' founder and Managing Partner.

BullFrog AI Announces Appointment of Enrique García-Rivera as Vice President of Artificial Intelligence

Retrieved on: 
Tuesday, July 11, 2023

GAITHERSBURG, Md., July 11, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Enrique García-Rivera, Ph.D., as its new Vice President of Artificial Intelligence.

Key Points: 
  • GAITHERSBURG, Md., July 11, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Enrique García-Rivera, Ph.D., as its new Vice President of Artificial Intelligence.
  • The appointment will further advance BullFrog AI’s best-in-class proprietary bfLEAP™ AI platform that is engineered to enable more accurate predictions of patient disease progression and improve the design of clinical trials to speed safe and effective drug development.
  • “We are excited to welcome Enrique to BullFrog AI.
  • His vast experience in developing machine learning models and managing large biological databases further augments BullFrog AI’s industry-leading capabilities.

Avalon GloboCare Provides Update on New Commercial Strategy

Retrieved on: 
Monday, July 10, 2023

FREEHOLD, N.J., July 10, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today provided the following letter to shareholders from the Company’s President and CEO, David Jin, M.D., Ph.D.:

Key Points: 
  • Avalon is dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services.
  • Our evolving strategy involves acquiring ownership or license rights to precision diagnostic assets, genetic testing and clinical laboratory companies through joint ventures, share ownership structures or distribution rights.
  • We intend to play a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results.
  • In turn, we believe our profit-sharing arrangement with LSM will result in significant future cash flow to Avalon.

Braven Launches New Unit to Invest In the Next Generation of Healthcare & Life Science Innovators

Retrieved on: 
Friday, July 7, 2023

Co-led by William Abecassis, Braven’s Managing Partner, and Dr. Sean Khozin, Senior Life Sciences & Healthcare Partner, the Unit supports the firm’s unique ‘co-building’ investment strategy.

Key Points: 
  • Co-led by William Abecassis, Braven’s Managing Partner, and Dr. Sean Khozin, Senior Life Sciences & Healthcare Partner, the Unit supports the firm’s unique ‘co-building’ investment strategy.
  • "Across healthcare and life sciences, there are countless opportunities for innovation.
  • To augment the Unit's capabilities, Braven has enlisted a team of specialized fellows with expertise spanning from pharma development to healthcare provision.
  • Braven is an early-stage investment firm focused on breakthrough innovation within regulated ecosystems, starting with financial services, insurance, and healthcare.

Relativity6 Welcomes 50th Customer, Advancing its Mission to Solve Industry Classification with Artificial Intelligence

Retrieved on: 
Thursday, July 6, 2023

This achievement strengthens its commitment to transform industry classification using advanced artificial intelligence across industries.

Key Points: 
  • This achievement strengthens its commitment to transform industry classification using advanced artificial intelligence across industries.
  • Relativity6 continues to provide AI-driven industry classification solutions that help businesses better understand what their customers and prospects actually do.
  • This milestone reflects our commitment to using AI to redefine and solve what is widely considered the hardest problem in business intelligence -  industry classification.
  • We're focused on pushing the boundaries of industry classification, shaping its future on a larger scale across industries and geographies."

Science activism is surging – which marks a culture shift among scientists

Retrieved on: 
Thursday, July 6, 2023

And during the same month in Norway, three scientists were arrested for protesting the nation’s slow-moving climate policy.

Key Points: 
  • And during the same month in Norway, three scientists were arrested for protesting the nation’s slow-moving climate policy.
  • We’re interested in how the surge in science activism may be changing the norms of scientific research.
  • With colleagues, we recently reviewed and summarized a growing body of studies examining how scientists are mobilizing for social activism and political protest.

A new wave of science activism

    • Science activism has long been considered taboo, as many in the field fear that politicizing science undermines its objectivity.
    • More recently, the election of Donald Trump in 2016 triggered a wave of political mobilization not seen in the United States since the Vietnam War era.
    • In the context of the COVID-19 pandemic, climate change activism, Black Lives Matter and the #MeToo movement, scientists have also mobilized, and science advocacy organizations are playing important roles.
    • A new course taught by an MIT physics professor titled “Scientist Activism: Gender, Race and Power” helps raise student awareness about the political nature of science.

Professional norms may be shifting

    • However, we also expect that impending crises, like climate change, may be driving acceptance of activism within the scientific community.
    • But this near-uniform level of support for political action suggests that the professional norms that have long sanctioned scientist activism may be shifting.
    • Scientist activism often entails some level of personal or professional risk.
    • Although they are more likely to be rewarded for this activity, they are exposed to greater risk for doing so.

Emerging lessons

    • Two lessons emerge from our research thus far.
    • First, our findings indicate that science activism may be gaining legitimacy within the scientific community.
    • Second, because race unevenly structures scientists’ experiences with activism, science activists can build on their current momentum by
      embracing intersectional solidarity.

Akamis Bio Strengthens Leadership Team with Key Executive Appointments

Retrieved on: 
Thursday, July 6, 2023

as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research.

Key Points: 
  • as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research.
  • “As CMO, Oliver’s decades of experience in oncology drug development will be critical as we advance our lead program, NG-350A, toward clinical proof-of-concept studies.
  • Dr. Kosa has also held leadership positions at XOMA, Bayer Healthcare, and Connecticut Innovations.
  • She joined Akamis Bio from the Parker Institute for Cancer Immunotherapy in San Francisco where she was Senior Director of Research and Development.

New Appointee Joins Citizens Coinage Advisory Committee As Member Specially Qualified in American History

Retrieved on: 
Wednesday, July 5, 2023

Washington, DC, July 05, 2023 (GLOBE NEWSWIRE) -- The United States Mint (Mint) announces the appointment of Dr. Christopher Capozzola to a four-year term on the Citizens Coinage Advisory Committee (CCAC) as the member Specially Qualified in American history.

Key Points: 
  • Washington, DC, July 05, 2023 (GLOBE NEWSWIRE) -- The United States Mint (Mint) announces the appointment of Dr. Christopher Capozzola to a four-year term on the Citizens Coinage Advisory Committee (CCAC) as the member Specially Qualified in American history.
  • Deputy Treasury Secretary Adeyemo appointed Dr. Capozzola on May 29, 2023, and he will be formally sworn in at the next public CCAC meeting.
  • Capozzola is Professor of History and Senior Associate Dean for Open Learning at the Massachusetts Institute of Technology (MIT).
  • At MIT, he teaches courses in political and legal history, war and the military, and the history of international migration.

DIII-D National Fusion Facility Completes Record-Breaking 1,600-Hour Research Campaign

Retrieved on: 
Wednesday, July 5, 2023

San Diego, CA, July 05, 2023 (GLOBE NEWSWIRE) -- The DIII-D National Fusion Facility completed its current two-year research campaign last week, closing out a series of experiments that pioneered many transformational advances for fusion energy.

Key Points: 
  • San Diego, CA, July 05, 2023 (GLOBE NEWSWIRE) -- The DIII-D National Fusion Facility completed its current two-year research campaign last week, closing out a series of experiments that pioneered many transformational advances for fusion energy.
  • The campaign included a record-breaking 1,600 hours of plasma research as part of 140 ground-breaking studies.
  • As research operations conclude, the facility will begin a slate of major upgrades over the next eight months to prepare for the next phase of research.
  • The record-breaking campaign saw the facility in operations for over 200 days.